These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 278414)

  • 21. [Results of the clinical study of a preparation of diiodobenzotef in malignant tumors].
    Karev NI; Garin AM; Blokhina NG; Pershin MP; Trapeznikova MF
    Klin Med (Mosk); 1975 May; 52(5):50-3. PubMed ID: 1133992
    [No Abstract]   [Full Text] [Related]  

  • 22. Phase II trials of the single agents baker's antifol, diaziquone, and epirubicin in advanced pancreatic cancer. Gastrointestinal Tumor Study Group.
    Cancer Treat Rep; 1987 Sep; 71(9):865-7. PubMed ID: 3476203
    [No Abstract]   [Full Text] [Related]  

  • 23. [Effect of the cytotoxic action preparation fotrin on the function of the adrenal cortex in the treatment of reticulodermia].
    Soloveĭ SN; Kalamkarian AA; Chumakov NN; Zavadskiĭ VN
    Vestn Dermatol Venerol; 1975 Dec; (12):8-11. PubMed ID: 1229676
    [No Abstract]   [Full Text] [Related]  

  • 24. Phase I-II diaziquone chemotherapy in brain tumors.
    Madajewicz S; Spaulding M; Bhimani S; Avellanosa A; DeLos Santos R; Perry A; Zeigler P; Kirshner J
    Cancer Treat Rep; 1984 Jun; 68(6):913-4. PubMed ID: 6733706
    [No Abstract]   [Full Text] [Related]  

  • 25. [Complex treatment of bladder cancer with pre- and postoperative chemotherapy].
    Klimenko IA; Goĭkhberg MI; Zaparin VK; Iaremko VN; Sakalo VS
    Urol Nefrol (Mosk); 1987; (1):26-8. PubMed ID: 3564196
    [No Abstract]   [Full Text] [Related]  

  • 26. Phase II evaluation of diaziquone in recurrent head and neck cancer.
    Kish JA; Ensley J; Al-Sarraf M
    Cancer Treat Rep; 1986 May; 70(5):671-2. PubMed ID: 3708616
    [No Abstract]   [Full Text] [Related]  

  • 27. Effect of AZQ (1,4-cyclohexadiene-1,4-diacarbamic acid-2,5-bis(1-aziridinyl)-3,6 -dioxodiethylester) in recurring supratentorial malignant brain gliomas--a Phase II study. EORTC Brain Tumour Cooperative Group.
    Eur J Cancer Clin Oncol; 1985 Jan; 21(1):143-6. PubMed ID: 4038653
    [No Abstract]   [Full Text] [Related]  

  • 28. Phase I study of diaziquone.
    Frytak S; Eagan RT; Ames MM; Creagan ET; Nichols WC
    Cancer Treat Rep; 1984; 68(7-8):975-8. PubMed ID: 6744349
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phase II trial of diaziquone in advanced upper aerodigestive cancer.
    Creagan ET; Long HJ; Kvols LK; Edmonson JH; O'Fallon JR
    Cancer Treat Rep; 1985 Jan; 69(1):141. PubMed ID: 3967258
    [No Abstract]   [Full Text] [Related]  

  • 30. Phase II study of diaziquone in advanced soft tissue and bony sarcoma: a Southwest Oncology Group study.
    Zidar BL; Baker LH; Rivkin SE; Balcerzak SP; Stephens RL
    Cancer Treat Rep; 1985 Sep; 69(9):1035-6. PubMed ID: 4028037
    [No Abstract]   [Full Text] [Related]  

  • 31. Phase II trial of diaziquone in advanced large bowel carcinoma in previously treated and untreated patients: a Southwest Oncology Group Study.
    Shildt R; Stephens RL; Subramanian VP; Baker LH; Fletcher WS; O'Bryan RM; McCracken JD
    Cancer Treat Rep; 1985 Jun; 69(6):709-10. PubMed ID: 4016775
    [No Abstract]   [Full Text] [Related]  

  • 32. [Antitumor activity and pharmacological properties of furizil].
    Stukov AN; Kraĭz BO; Aleksandrov VA; Ivin BA; Filov VA
    Vopr Onkol; 1985; 31(5):52-4. PubMed ID: 4013130
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phase II trial of diaziquone in anthracycline-resistant adult soft tissue and bone sarcoma patients: a Southeastern Cancer Study Group Trial.
    Chan C; Bartolucci A; Brenner D; Presant C; Davila E; Carpenter J; Greco FA; Clamon G; Moore J
    Cancer Treat Rep; 1986 Mar; 70(3):427-8. PubMed ID: 3456834
    [No Abstract]   [Full Text] [Related]  

  • 34. Estrogen-linked cytotoxic agents of potential value for the treatment of breast cancer.
    Leclercq G; Devleeschouwer N; Legros N; Heuson JC
    Eur J Cancer (1965); 1980; Suppl 1():287-93. PubMed ID: 7318866
    [No Abstract]   [Full Text] [Related]  

  • 35. Therapeutic effects of BM 12,531 (Prop. INN azimexon).
    Bicker U
    Recent Results Cancer Res; 1980; 75():147-52. PubMed ID: 7232826
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phase I study of aziridinylbenzoquinone (AZQ, NSC 182986) in children with cancer.
    Tan CT; Hancock CH; Mondora A; Hoffman NW
    Cancer Res; 1984 Feb; 44(2):831-5. PubMed ID: 6692381
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Tactics of cytostatic therapy of primary and secondary (post-erythremic) myelofibrosis].
    Demidova AV; Sysoeva NA
    Probl Gematol Pereliv Krovi; 1976 Jul; 21(7):23-7. PubMed ID: 1071792
    [No Abstract]   [Full Text] [Related]  

  • 38. Preliminary communication--treatment of primary brain tumors recurrent after irradiation with aziridinylbenzoquinone (AZQ;NSC-182986).
    Eagan RT; Dinapoli RP; Hermann RC; Groover RV; Layton DD
    Am J Clin Oncol; 1983 Oct; 6(5):577-8. PubMed ID: 6613923
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of the immunomodulant 2-cyanaziridine derivative BM 41.332 on adjuvant arthritis in the rat.
    Bicker U
    Arzneimittelforschung; 1982; 32(7):746-52. PubMed ID: 6889876
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Isomer-dependent cytostatic activity of bis(1-aziridinyl)cyclophosphazenes.
    van der Huizen AA; Wilting T; van de Grampel JC; Lelieveld P; van der Meer-Kalverkamp A; Lamberts HB; Mulder NH
    J Med Chem; 1986 Aug; 29(8):1341-5. PubMed ID: 3735303
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.